

Anti-PDCD1/PD-1/CD279 Antibody (Spartalizumab)

Introduction

Spartalizumab (PDR001) is a humanized Ig4 monoclonal antibody that binds to PD-1, and block PD-L1 Interaction with PD-L2. Spartalizumab can be used in the study of anaplastic thyroid cancer (ATC).

Product parameters

Alternative Names	PDR001, BAP049
Target Accession	Q15116
Target	PDCD1 / PD-1 / CD279
CAS number	1935694-88-4
Molecular Weight	143.14 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human PD-1 His at 2 ug/mL can bind Anti-PDCD1/PD-1/CD279 Antibody (Spartalizumab), EC50=0.01484 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

